A recent study evaluated the safety and efficacy of a vaccine developed to prevent the development of the potentially life-threatening condition toxic shock syndrome.
Patients with rheumatoid arthritis are more susceptible to infections and yet a significant percentage of this target population has not received an influenza or pneumonia vaccination.